Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 31, 2018

Primary Completion Date

December 31, 2020

Study Completion Date

June 30, 2024

Conditions
Recurrent Malignant Solid NeoplasmRecurrent OsteosarcomaRefractory Malignant Solid NeoplasmRefractory Osteosarcoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pepinemab

Given IV

OTHER

Pharmacological Study

Correlative studies

Trial Locations (24)

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Medical Center, Washington D.C.

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

23507

Children's Hospital of The King's Daughters, Norfolk

30322

Children's Healthcare of Atlanta - Egleston, Atlanta

35233

Children's Hospital of Alabama, Birmingham

38105

Saint Jude Children's Research Hospital, Memphis

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Riley Hospital for Children, Indianapolis

48109

C S Mott Children's Hospital, Ann Arbor

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

60611

Lurie Children's Hospital-Chicago, Chicago

63110

Washington University School of Medicine, St Louis

77030

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston

78229

University of Texas Health Science Center at San Antonio, San Antonio

80045

Children's Hospital Colorado, Aurora

90027

Children's Hospital Los Angeles, Los Angeles

92868

Children's Hospital of Orange County, Orange

94158

UCSF Medical Center-Mission Bay, San Francisco

98105

Seattle Children's Hospital, Seattle

06520

Yale University, New Haven

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Children's Oncology Group

NETWORK

NCT03320330 - Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors | Biotech Hunter | Biotech Hunter